semaglutide and muscle weakness Does GLP-1 Cause Pain? Evidence Management Careful about Semaglutide #drskgupta #ShivamNursingHome

A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity but thats not the question we ought to be asking

Additional information Responsible Editor: Jianxiong Jiang

PlexusDx supports dose escalation without price increases

Gastro-intestinale effecten: Misselijkheid is het meest voorkomende symptoom, met meldingen van tot wel 60% bij deelnemers bij hogere doseringen

More severe reactions could include difficulty breathing, swelling of the face, lips, tongue, or throat, which would require immediate emergency medical treatment

Semaglutide treatment Our patients need regulation of sugar levels , necessary regulation of cholesterol levels , both in the body improvement in inflammation and inflammation markers The fact that we see our patients cardiovascular risks are also significantly reduced shows us